Yahoo Finance highlighted three top dividend stocks trading near their 52-week lows, a pattern that has drawn attention as the S&P 500 hits new highs in 2026 while many income-oriented names languish. The divergence reflects a market where AI and hyperscaler enthusiasm has crowded out defensive sectors, leaving some established dividend payers at depressed valuations despite intact fundamentals.
Novo Nordisk (NYSE: NVO) exemplifies the dynamic. Shares closed at $45.79, within a 52-week range of $35.12 to $64.16, and the stock has fallen roughly 17% over the past year. The Danish pharmaceutical giant trades at about 11 times trailing earnings and offers a dividend yield of 5.30%. Pressure stems from intensifying competition in the GLP-1 weight-loss and diabetes market, where rival Eli Lilly has captured investor imagination, while Novo's growth rate has disappointed.
Yet the company still owns Wegovy and Ozempic, two of the world's leading GLP-1 drugs, and a higher-dose version of semaglutide has shown significantly greater weight-loss potential in trials. That pipeline optionality, combined with a gross margin above 80%, suggests the sell-off may reflect sentiment more than structural impairment.
In the REIT space, Realty Income (NYSE: O) trades at $62.40 against a 52-week range of $55.86 to $67.94, yielding 5.19%. The monthly dividend payer has raised its payout for over 31 consecutive years, including through recessions and the pandemic. Management guides the 2026 payout ratio at roughly 73% of funds from operations, leaving a comfortable coverage cushion.